According to an editorial published in the New England Journal of Medicine, it is too early to rule out concerns about a possible Vytorin cancer connection that was identified in recent study data. The makers of Vytorin had previously sent a letter to

WASHINGTON (Reuters) - Two U.S. congressmen asked Merck & Co and Schering-Plough Corp for more information about a report the companies submitted to regulators assessing a possible link between cholesterol drug Vytorin and cancer, a letter released on

CHOLESTEROL COUNT: Three studies of the cholesterol-lowering drug Vytorin, funded by its makers, can't prove or rule out a possible link to a higher risk of cancer that emerged this summer. Get stories by e-mail on this topic. EXPERT OPINION: Top

Novacea Inc. of South San Francisco and privately held Transcept Pharmaceuticals Inc. of Richmond will merge, blending a company with a recently failed Big Pharma collaboration with one on the verge of seeking FDA approval for its first drug. Under

2008-09-02 22:49:01 - companies, was down 5%. "With the big pharma bids for Genentech and ImClone being considered in their respective board rooms, investors' attention on biotech waned slightly in August," said G. Steven Burrill, CEO,